ICE regimen
|
WikiDoc Resources for ICE regimen |
|
Articles |
|---|
|
Most recent articles on ICE regimen Most cited articles on ICE regimen |
|
Media |
|
Powerpoint slides on ICE regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on ICE regimen at Clinical Trials.gov Clinical Trials on ICE regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on ICE regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on ICE regimen Discussion groups on ICE regimen Patient Handouts on ICE regimen Directions to Hospitals Treating ICE regimen Risk calculators and risk factors for ICE regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for ICE regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:Carboplatin/Etoposide/Ifosfamide; CBDCA/IFF/VP-16; ICE; ICE Regimen; ICE regimen; Ifosfamide-Carboplatin-Etoposide Regimen
Overview
ICE regimen refers to a chemotherapy regimen consisting of ifosfamide, carboplatin and etoposide used in the treatment of non-Hodgkin and hodgkin lymphomas.[1][2]
Regimen
IIfosfamide CCarboplatin EEtoposide
Indications
- Relapsed and refractory non-Hodgkin and Hodgkin lymphomas.[1]
References
- ↑ 1.0 1.1 Xia W, Ma CK, Reid C, Bai L, Wong K, Kerridge I; et al. (2014). "Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation". J Clin Apher. 29 (6): 322–30. doi:10.1002/jca.21340. PMID 24944079.
- ↑ "NCI Thesaurus".